{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:23:57Z","timestamp":1790796237671,"version":"4.1.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2014,6,1]],"date-time":"2014-06-01T00:00:00Z","timestamp":1401580800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1007\/s40265-014-0239-z","type":"journal-article","created":{"date-parts":[[2014,6,11]],"date-time":"2014-06-11T12:05:33Z","timestamp":1402488333000},"page":"999-1016","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Certolizumab Pegol: A Review of Its Use in Patients with Axial Spondyloarthritis or Psoriatic Arthritis"],"prefix":"10.1007","volume":"74","author":[{"given":"Sohita","family":"Dhillon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,6,12]]},"reference":[{"issue":"5","key":"239_CR1","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nrrheum.2012.33","volume":"8","author":"A Tubergen van","year":"2012","unstructured":"van Tubergen A, Weber U. Diagnosis and classification in spondyloarthritis: identifying a chameleon. Nat Rev Rheumatol. 2012;8(5):253\u201361.","journal-title":"Nat Rev Rheumatol"},{"issue":"6","key":"239_CR2","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1136\/annrheumdis-2012-202908","volume":"72","author":"IE Horst-Bruinsma van der","year":"2013","unstructured":"van der Horst-Bruinsma IE. Treatment of non-radiographic axial spondyloarthritis: it is only the beginning. Ann Rheum Dis. 2013;72(6):789\u201390.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"239_CR3","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1136\/ard.2009.108233","volume":"68","author":"M Rudwaleit","year":"2009","unstructured":"Rudwaleit M, van der Heijde D, Landewe R, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis. 2009;68(6):777\u201383.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"239_CR4","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/rheumatology\/keh358","volume":"44","author":"S Paul","year":"2005","unstructured":"Paul S, Keat A. Assessment of patients with spondyloarthropathies for treatment with tumour necrosis factor alpha blockade. Rheumatology. 2005;44(1):17\u201323.","journal-title":"Rheumatology"},{"issue":"1","key":"239_CR5","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1093\/rheumatology\/36.1.38","volume":"36","author":"JD Canete","year":"1997","unstructured":"Canete JD, Llena J, Collado A, et al. Comparative cytokine gene expression in synovial tissue of early rheumatoid arthritis and seronegative spondyloarthropathies. Br J Rheumatol. 1997;36(1):38\u201342.","journal-title":"Br J Rheumatol"},{"issue":"6","key":"239_CR6","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1002\/1529-0131(200006)43:6<1244::AID-ANR7>3.0.CO;2-2","volume":"43","author":"CL Danning","year":"2000","unstructured":"Danning CL, Illei GG, Hitchon C, et al. Macrophage-derived cytokine and nuclear factor kappaB p65 expression in synovial membrane and skin of patients with psoriatic arthritis. Arthritis Rheum. 2000;43(6):1244\u201356.","journal-title":"Arthritis Rheum"},{"issue":"10","key":"239_CR7","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1093\/rheumatology\/33.10.927","volume":"33","author":"J Gratacos","year":"1994","unstructured":"Gratacos J, Collado A, Filella X, et al. Serum cytokines (IL-6, TNF-alpha, IL-1 beta and IFN-gamma) in ankylosing spondylitis: a close correlation between serum IL-6 and disease activity and severity. Br J Rheumatol. 1994;33(10):927\u201331.","journal-title":"Br J Rheumatol"},{"issue":"1","key":"239_CR8","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s40265-013-0009-3","volume":"73","author":"ED Deeks","year":"2013","unstructured":"Deeks ED. Certolizumab pegol: a review of its use in the management of rheumatoid arthritis. Drugs. 2013;73(1):75\u201397.","journal-title":"Drugs"},{"issue":"6","key":"239_CR9","doi-asserted-by":"crossref","first-page":"407","DOI":"10.2165\/11202800-000000000-00000","volume":"23","author":"ST Duggan","year":"2009","unstructured":"Duggan ST, Keam SJ. Certolizumab pegol: in rheumatoid arthritis. BioDrugs. 2009;23(6):407\u201317.","journal-title":"BioDrugs"},{"key":"239_CR10","unstructured":"European Medicines Agency. Cimzia (certolizumab pegol): summary of product characteristics. 2014. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/001037\/WC500069763.pdf . Accessed 8 May 2014."},{"key":"239_CR11","unstructured":"UCB Inc. Cimzia (certolizumab pegol): US prescribing information. 2013. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/125160s215lbl.pdf . Accessed 8 MAy 2014."},{"key":"239_CR12","unstructured":"European Medicines Agency. Assessment report for cimzia (EMEA\/H\/C\/001037). 2009. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/001037\/WC500069735.pdf . Accessed 21 Jan 2014."},{"issue":"1","key":"239_CR13","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1136\/annrheumdis-2013-204231","volume":"73","author":"R Landewe","year":"2014","unstructured":"Landewe R, Braun J, Deodhar A, et al. Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled phase 3 study. Ann Rheum Dis. 2014;73(1):39\u201347.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"239_CR14","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1136\/annrheumdis-2013-203696","volume":"73","author":"PJ Mease","year":"2014","unstructured":"Mease PJ, Fleischmann R, Deodhar AA, et al. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). Ann Rheum Dis. 2014;73(1):48\u201355.","journal-title":"Ann Rheum Dis"},{"key":"239_CR15","unstructured":"European Medicines Agency. Cimzia: assessment report (EMEA\/H\/C\/001037\/II\/29). 2013. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Assessment_Report_-_Variation\/human\/001037\/WC500153994.pdf . Accessed 18 Dec 2013."},{"key":"239_CR16","unstructured":"European Medicines Agency. Cimzia: assessment report (EMEA\/H\/C\/001037\/II\/27). 2013. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Assessment_Report_-_Variation\/human\/001037\/WC500159001.pdf . Accessed 8 May 2014."},{"issue":"Suppl 10","key":"239_CR17","first-page":"S243","volume":"64","author":"J Sieper","year":"2012","unstructured":"Sieper J, Kivitz AJ, Van Tubergen AM, et al. Rapid improvements in patient reported outcomes with certolizumab pegol in patients with axial spondyloarthritis, including ankylosing spondyltitis and non-radiographic axial spondyloarthritis: 24\u00a0week results of a phase 3 double blind randomized placebo-controlled study [abstract no. 558]. Arthritis Rheum. 2012;64(Suppl 10):S243.","journal-title":"Arthritis Rheum"},{"issue":"10 Suppl","key":"239_CR18","first-page":"S767","volume":"65","author":"R Landewe","year":"2013","unstructured":"Landewe R, Rudwaleit M, Van Der Heijde D, et al. Effect of certolizumab pegol over 48\u00a0weeks in patients with axial spondyloarthritis, including ankylosing spondylitis and non-radiographic axial spondyloarthritis [abstract no. 1799]. Arthritis Rheum. 2013;65(10 Suppl):S767.","journal-title":"Arthritis Rheum"},{"issue":"Suppl 10","key":"239_CR19","first-page":"S730","volume":"64","author":"D Heijde van Der","year":"2012","unstructured":"van Der Heijde D, Maksymowych WP, Landewe RBM, et al. Effect of certolizumab pegol on inflammation of spine and sacroiliac joints in patients with axial spondyloarthritis: 12\u00a0week magnetic resonance imaging results of a phase 3 double blind randomized placebo-controlled study [abstract no. 1705]. Arthritis Rheum. 2012;64(Suppl 10):S730.","journal-title":"Arthritis Rheum"},{"issue":"Suppl 10","key":"239_CR20","first-page":"S592","volume":"64","author":"D Heijde van Der","year":"2012","unstructured":"van Der Heijde D, Braun J, Rudwaleit M, et al. Increased participation in daily activities after 24\u00a0weeks of certolizumab pegol treatment of axial spondyloarthritis patients, including patients with ankylosing spondylitis: results of a phase 3 double-blind randomized placebo-controlled study [abstract no. 1372]. Arthritis Rheum. 2012;64(Suppl 10):S592.","journal-title":"Arthritis Rheum"},{"issue":"Suppl 10","key":"239_CR21","first-page":"S644","volume":"65","author":"D Heijde van Der","year":"2013","unstructured":"van Der Heijde D, Braun J, Rudwaleit M, et al. Reduction of disease burden on workplace and household productivity in axial spondyloarthritis, including ankylosing spondylitis and non-radiographic axial spondyloarthritis, over 48\u00a0weeks of treatment with certolizumab pegol [abstract no. 1520]. Arthritis Rheum. 2013;65(Suppl 10):S644.","journal-title":"Arthritis Rheum"},{"issue":"Suppl 10","key":"239_CR22","first-page":"S132","volume":"65","author":"P Mease","year":"2013","unstructured":"Mease P, Fleischmann R, Wollenhaupt J, et al. Effect of certolizumab pegol over 48\u00a0weeks on signs and symptoms in patients with psoriatic arthritis with and without prior tumor necrosis factor inhibitor [abstract no. 312]. Arthritis Rheum. 2013;65(Suppl 10):S132.","journal-title":"Arthritis Rheum"},{"issue":"7","key":"239_CR23","doi-asserted-by":"crossref","first-page":"A569","DOI":"10.1016\/j.jval.2013.08.1524","volume":"16","author":"D Gladman","year":"2013","unstructured":"Gladman D, Fleischmann R, Coteur G, et al. Long-term maintenance of improvements in multiple facets of psoriatic arthritis with certolizumab pegol: 48-week patient-reported outcome results of the RAPID-PSA study [abstract no. PMS81]. Value Health. 2013;16(7):A569.","journal-title":"Value Health"},{"issue":"Suppl 1","key":"239_CR24","first-page":"i163","volume":"52","author":"A Kavanaugh","year":"2013","unstructured":"Kavanaugh A, Gladman D, van der Heijde D, et al. Improvements in productivity at paid work and within household, and increased participation in daily activities after 24\u00a0weeks of certolizumab pegol treatment of patients with psoriatic arthritis: results of a phase III double-blind randomized placebo-controlled study [abstract no. 286]. Rheumatology. 2013;52(Suppl 1):i163\u20134.","journal-title":"Rheumatology"},{"issue":"Suppl 10","key":"239_CR25","first-page":"S140","volume":"65","author":"A Kavanaugh","year":"2013","unstructured":"Kavanaugh A, Gladman D, Van Der Heijde D, et al. Reduction of disease burden on workplace and household productivity in psoriatic arthritis over 48\u00a0weeks of treatment with certolizumab pegol [abstract no. 326]. Arthritis Rheum. 2013;65(Suppl 10):S140.","journal-title":"Arthritis Rheum"},{"key":"239_CR26","unstructured":"Landewe RBM, Rudwaleit M, Van Der Heijde D, et al. Effect of certolizumab pegol on signs and symptoms of ankylosing spondyltitis and non-radiographic axial spondyloarthritis: 24\u00a0week results of a double blind randomized placebo-controlled phase 3 axial spondyloarthritis study [abstract no. 777]. Arthritis Rheum. 2012;64(10 Suppl):S336\u2013S7."},{"issue":"Suppl 3","key":"239_CR27","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1136\/annrheumdis-2013-eular.2023","volume":"72","author":"PJ Mease","year":"2013","unstructured":"Mease PJ, Fleischmann R, Wollenhaupt J, et al. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis from the RAPID-PsA study: impact of baseline skin involvement and prior anti-TNF therapy [abstract no. SAT0298]. Ann Rheum Dis. 2013;72(Suppl 3):684.","journal-title":"Ann Rheum Dis"},{"key":"239_CR28","author":"D Heijde van der","year":"2013","unstructured":"van der Heijde D, Fleischmann R, Wollenhaupt J, et al. Effect of different imputation approaches on the evaluation of radiographic progression in patients with psoriatic arthritis: results of the RAPID-PsA 24-week phase III double-blind randomised placebo-controlled study of certolizumab pegol. Ann Rheum Dis. 2013. doi: 10.1136\/annrheumdis-2013-203697 .","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"239_CR29","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1002\/art.34436","volume":"64","author":"A Kavanaugh","year":"2012","unstructured":"Kavanaugh A, van der Heijde D, McInnes IB, et al. Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial. Arthritis Rheum. 2012;64(8):2504\u201317.","journal-title":"Arthritis Rheum"},{"key":"239_CR30","doi-asserted-by":"crossref","unstructured":"Gladman D, Fleischmann R, Coteur G, et al. Effect of certolizumab pegol on multiple facets of psoriatic arthritis as reported by patients: 24-week patient-reported outcome results of the RAPID-PsA study. Arthritis Care Res. 2013. doi: 10.1002\/acr.22256 .","DOI":"10.1002\/acr.22256"},{"key":"239_CR31","doi-asserted-by":"crossref","unstructured":"Bykerk VP, Cush J, Winthrop K, et al. Update on the safety profile of certolizumab pegol in rheumatoid arthritis: an integrated analysis from clinical trials. Ann Rheum Dis. 2013. doi: 10.1136\/annrheumdis-2013-203660 .","DOI":"10.1136\/annrheumdis-2013-203660"},{"issue":"1","key":"239_CR32","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1136\/annrheumdis-2013-203419","volume":"73","author":"JS Smolen","year":"2014","unstructured":"Smolen JS, Braun J, Dougados M, et al. Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Ann Rheum Dis. 2014;73(1):6\u201316.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"239_CR33","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1136\/ard.2011.151563","volume":"70","author":"D Heijde van der","year":"2011","unstructured":"van der Heijde D, Sieper J, Maksymowych WP, et al. 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann Rheum Dis. 2011;70(6):905\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"239_CR34","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1136\/ard.2011.151027","volume":"70","author":"J Braun","year":"2011","unstructured":"Braun J, van den Berg R, Baraliakos X, et al. 2010 update of the ASAS\/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis. 2011;70(6):896\u2013904.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"239_CR35","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1136\/annrheumdis-2011-200350","volume":"71","author":"L Gossec","year":"2012","unstructured":"Gossec L, Smolen JS, Gaujoux-Viala C, et al. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis. 2012;71(1):4\u201312.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"239_CR36","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1136\/ard.2008.094946","volume":"68","author":"CT Ritchlin","year":"2009","unstructured":"Ritchlin CT, Kavanaugh A, Gladman DD, et al. Treatment recommendations for psoriatic arthritis. Ann Rheum Dis. 2009;68(9):1387\u201394.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"239_CR37","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1093\/rheumatology\/ket187","volume":"52","author":"LC Coates","year":"2013","unstructured":"Coates LC, Tillett W, Chandler D, et al. The 2012 BSR and BHPR guideline for the treatment of psoriatic arthritis with biologics. Rheumatology. 2013;52(10):1754\u20137.","journal-title":"Rheumatology"},{"key":"239_CR38","unstructured":"European Medicines Agency. Humira (adalimumab): summary of product characteristics. 2013. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000481\/WC500050870.pdf . Accessed 8 May 2014."},{"issue":"Suppl 6","key":"239_CR39","doi-asserted-by":"crossref","first-page":"vi37","DOI":"10.1093\/rheumatology\/kes283","volume":"51","author":"EM Ruderman","year":"2012","unstructured":"Ruderman EM. Overview of safety of non-biologic and biologic DMARDs. Rheumatology. 2012;51(Suppl 6):vi37\u201343.","journal-title":"Rheumatology"},{"issue":"11","key":"239_CR40","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1002\/ibd.20225","volume":"13","author":"A Nesbitt","year":"2007","unstructured":"Nesbitt A, Fossati G, Bergin M, et al. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents. Inflamm Bowel Dis. 2007;13(11):1323\u201332.","journal-title":"Inflamm Bowel Dis"},{"issue":"6","key":"239_CR41","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1097\/MIB.0b013e318280b169","volume":"19","author":"N Ueda","year":"2013","unstructured":"Ueda N, Tsukamoto H, Mitoma H, et al. The cytotoxic effects of certolizumab pegol and golimumab mediated by transmembrane tumor necrosis factor alpha. Inflamm Bowel Dis. 2013;19(6):1224\u201331.","journal-title":"Inflamm Bowel Dis"},{"issue":"2","key":"239_CR42","first-page":"225","volume":"31","author":"SK Heathfield","year":"2013","unstructured":"Heathfield SK, Parker B, Zeef LAH, et al. Certolizumab pegol attenuates the pro-inflammatory state in endothelial cells in a manner that is atheroprotective. Clin Exp Rheumatol. 2013;31(2):225\u201333.","journal-title":"Clin Exp Rheumatol"},{"issue":"1\u20132","key":"239_CR43","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jim.2009.06.009","volume":"348","author":"R Palframan","year":"2009","unstructured":"Palframan R, Airey M, Moore A, et al. Use of biofluorescence imaging to compare the distribution of certolizumab pegol, adalimumab, and infliximab in the inflamed paws of mice with collagen-induced arthritis. J Immunol Methods. 2009;348(1\u20132):36\u201341.","journal-title":"J Immunol Methods"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-014-0239-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-014-0239-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-014-0239-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T15:41:37Z","timestamp":1559490097000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-014-0239-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6]]},"references-count":43,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["239"],"URL":"https:\/\/doi.org\/10.1007\/s40265-014-0239-z","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,6]]}}}